{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T18:03:54Z","timestamp":1772820234861,"version":"3.50.1"},"reference-count":68,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The ALTA-1\u2009L trial and EXP-3B arm of NCT01970865 trial found that both brigatinib and lorlatinib showed durable and robust responses in treating ALK-positive non-small cell lung cancer (NSCLC) patients. However, brigatinib and lorlatinib treatments are costly and need indefinite administration until the disease progression. Thus, it remains uncertain whether using brigatinib followed by lorlatinib before chemotherapy is cost-effective compared to reserving these two drugs until progression after chemotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We used a Markov model to assess clinical outcomes and healthcare costs of treating ALK-positive NSCLC individuals with brigatinib followed by lorlatinib before chemotherapy versus a strategy of reserving these drugs until progression after chemotherapy. Transition probabilities were estimated using parametric survival modeling based on multiple clinical trials. The drug acquisition costs, adverse events costs, administration costs were extracted from published studies before and publicly available data. We calculated lifetime direct healthcare costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios from the perspective of a United States payer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Our base-case analysis indicated that the incremental cost-effectiveness ratios of using first-line brigatinib followed by lorlatinib compared with second-line brigatinib followed by lorlatinib is $-400,722.09\/QALY which meant that second-line brigatinib followed by lorlatinib had less costs and better outcomes. Univariate sensitivity analysis indicated the results were most sensitive to the cost of brigatinib. Probability sensitivity analysis revealed that using brigatinib followed by lorlatinib before chemotherapy had a 0% probability of cost-effectiveness versus delaying these two drugs until progression after chemotherapy at a willingness-to-pay threshold of $150,000 per QALY. Sensitivity analyses conducted revealed the robustness of this result, as incremental cost-effectiveness ratios never exceeded the willingness-to-pay threshold.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Using brigatinib as first-line treatment followed by lorlatinib for ALK-positive NSCLC may not be cost-effective given current pricing from the perspective of a United States payer. Delaying brigatinib followed by lorlatinib until subsequent lines of treatment may be a reasonable strategy that could limit healthcare costs without affecting clinical outcomes. More mature data are needed to better estimate cost-effectiveness in this setting.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2024.1213318","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T05:20:34Z","timestamp":1707974434000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer"],"prefix":"10.3389","volume":"12","author":[{"given":"Wenjie","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gengwei","family":"Huo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,15]]},"reference":[{"key":"ref1","first-page":"1553","article-title":"Global, regional, and National Cancer Incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 Cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study","volume-title":"JAMA Oncol","author":"Fitzmaurice","year":"2018"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1056\/NEJMra1703413","article-title":"Precision diagnosis and treatment for advanced non-small-cell lung Cancer","volume":"377","author":"Reck","year":"2017","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S1470-2045(17)30694-0","article-title":"Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study","volume":"19","author":"Herbst","year":"2018","journal-title":"Lancet Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3322\/caac.21565","article-title":"Cancer treatment and survivorship statistics, 2019","volume":"69","author":"Miller","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1158\/1078-0432.CCR-08-0168","article-title":"EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer","volume":"14","author":"Koivunen","year":"2008","journal-title":"Clin Cancer Res"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1002\/cncr.24181","article-title":"The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS","volume":"115","author":"Wong","year":"2009","journal-title":"Cancer"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"4273","DOI":"10.1158\/1078-0432.CCR-13-0318","article-title":"ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer","volume":"19","author":"Gainor","year":"2013","journal-title":"Clin Cancer Res"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.cell.2007.11.025","article-title":"Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer","volume":"131","author":"Rikova","year":"2007","journal-title":"Cell"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nm.2658","article-title":"RET, ROS1 and ALK fusions in lung cancer","volume":"18","author":"Takeuchi","year":"2012","journal-title":"Nat Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus Crizotinib in untreated ALK-positive non-small-cell lung Cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","volume":"389","author":"Soria","year":"2017","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1158\/2159-8290.CD-16-1123","article-title":"Targeting ALK: precision medicine takes on drug resistance","volume":"7","author":"Lin","year":"2017","journal-title":"Cancer Discov"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1311107","article-title":"Ceritinib in ALK-rearranged non-small-cell lung cancer","volume":"370","author":"Shaw","year":"2014","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(15)00488-X","article-title":"Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial","volume":"17","author":"Shaw","year":"2016","journal-title":"Lancet Oncol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1200\/JCO.2014.59.0539","article-title":"Clinical experience with Crizotinib in patients with advanced ALK-rearranged non-small-cell lung Cancer and brain metastases","volume":"33","author":"Costa","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","article-title":"Molecular mechanisms of resistance to first-and second-generation ALK inhibitors in ALK-rearranged lung Cancer","volume":"6","author":"Gainor","year":"2016","journal-title":"Cancer Discov"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"7535","DOI":"10.1073\/pnas.1019559108","article-title":"Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK","volume":"108","author":"Katayama","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S1470-2045(16)30392-8","article-title":"Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1\/2 trial","volume":"17","author":"Gettinger","year":"2016","journal-title":"Lancet Oncol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"4948","DOI":"10.1021\/acs.jmedchem.6b00306","article-title":"Discovery of Brigatinib (AP26113), a phosphine oxide-containing, potent, orally active inhibitor of anaplastic lymphoma kinase","volume":"59","author":"Huang","year":"2016","journal-title":"J Med Chem"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"14768","DOI":"10.1038\/ncomms14768","article-title":"Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer","volume":"8","author":"Uchibori","year":"2017","journal-title":"Nat Commun"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1200\/JCO.2016.71.5904","article-title":"Brigatinib in patients with Crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung Cancer: a randomized, Multicenter phase II trial","volume":"35","author":"Kim","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1200\/JCO.2017.77.5841","article-title":"Exploratory analysis of Brigatinib activity in patients with anaplastic lymphoma kinase-positive non-small-cell lung Cancer and brain metastases in two clinical trials","volume":"36","author":"Camidge","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus Crizotinib inALK-positive non\u2013small-cell lung Cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11523-012-0250-9","article-title":"ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC","volume":"8","author":"Casaluce","year":"2013","journal-title":"Target Oncol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ajco.12754","article-title":"Treatment of ALK-rearranged non-small cell lung cancer: a review of the landscape and approach to emerging patterns of treatment resistance in the Australian context","volume":"13","author":"Itchins","year":"2017","journal-title":"Asia Pac J Clin Oncol"},{"key":"ref27","article-title":"Clinical practice guidelines in non-small cell lung cancer","year":"2021"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","article-title":"Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study","volume":"19","author":"Solomon","year":"2018","journal-title":"Lancet Oncol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"970","DOI":"10.18553\/jmcp.2022.28.9.970","article-title":"The cost-effectiveness of brigatinib in adult patients with ALK inhibitor-naive ALK-positive non-small cell lung cancer from a US perspective","volume":"28","author":"Cranmer","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1177\/10781552211073468","article-title":"Brigatinib is a cost-effective treatment in first-line anaplastic lymphoma kinase mutation-positive (ALK\u2009+\u2009) advanced non-small cell lung cancer (NSCLC) with brain metastases","volume":"28","author":"Giuliani","year":"2022","journal-title":"J Oncol Pharm Pract"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"985834","DOI":"10.3389\/fpubh.2022.985834","article-title":"Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China","volume":"10","author":"Luo","year":"2022","journal-title":"Front Public Health"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1016\/j.clinthera.2011.09.016","article-title":"Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China","volume":"33","author":"Wu","year":"2011","journal-title":"Clin Ther"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S1470-2045(12)70063-3","article-title":"Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial","volume":"13","author":"Paz-Ares","year":"2012","journal-title":"Lancet Oncol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ejca.2020.02.022","article-title":"Weekly paclitaxel plus bevacizumab versus docetaxel as second-or third-line treatment in advanced non-squamous non-small-cell lung cancer: results of the IFCT-1103 ULTIMATE study","volume":"131","author":"Cortot","year":"2020","journal-title":"Eur J Cancer"},{"key":"ref37","first-page":"1","article-title":"United States life tables, 2018","volume":"69","author":"Arias","year":"2020","journal-title":"Natl Vital Stat Rep"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1200\/JCO.2000.18.10.2095","article-title":"Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy","volume":"18","author":"Shepherd","year":"2000","journal-title":"J Clin Oncol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"e0258605","DOI":"10.1371\/journal.pone.0258605","article-title":"Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer","volume":"16","author":"Liu","year":"2021","journal-title":"PLoS One"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1080\/14737167.2021.1899813","article-title":"First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China","volume":"21","author":"Yang","year":"2021","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"ref41","article-title":"MENET.com.cn","year":"2022"},{"key":"ref42","article-title":"YAOZH.com","year":"2022"},{"key":"ref43","article-title":"Center for Medicare and Medicaid Services: 2020 physician fee schedule","year":"2020"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","article-title":"Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Moreau","year":"2017","journal-title":"Ann Oncol"},{"key":"ref45","article-title":"Center for Medicare and Medicaid Services: 2020 Q1 clinical laboratory fee schedule","year":"2020"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1019826","DOI":"10.3389\/fphar.2022.1019826","article-title":"Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer","volume":"13","author":"You","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/bmb\/ldq033","article-title":"Health outcomes in economic evaluation: the QALY and utilities","volume":"96","author":"Whitehead","year":"2010","journal-title":"Br Med Bull"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1097\/JTO.0b013e318299243b","article-title":"Health-related quality of life and utility in patients with advanced non-small-cell lung cancer: a prospective cross-sectional patient survey in a real-world setting","volume":"8","author":"Chouaid","year":"2013","journal-title":"J Thorac Oncol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1111\/ajco.12477","article-title":"Health state utilities in non-small cell lung cancer: an international study. Asia Pac","volume":"13","author":"Nafees","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"e210037","DOI":"10.1001\/jamanetworkopen.2021.0037","article-title":"Cost-effectiveness of atezolizumab plus bevacizumab vs sorafenib as first-line treatment of unresectable hepatocellular carcinoma","volume":"4","author":"Su","year":"2021","journal-title":"JAMA Netw Open"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: a measure of health status from the EuroQol group","volume":"33","author":"Rabin","year":"2001","journal-title":"Ann Med"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s11096-020-01076-3","article-title":"Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer","volume":"42","author":"Lin","year":"2020","journal-title":"Int J Clin Pharm"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.lungcan.2018.03.008","article-title":"Economic impact of preventing brain metastases with alectinib in ALK-positive non-small cell lung cancer","volume":"119","author":"Burudpakdee","year":"2018","journal-title":"Lung Cancer"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1080\/13696998.2018.1443111","article-title":"Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States","volume":"21","author":"Zhou","year":"2018","journal-title":"J Med Econ"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1080\/13696998.2020.1762620","article-title":"Economic burden in patients with ALK\u2009+\u2009non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors","volume":"23","author":"Lin","year":"2020","journal-title":"J Med Econ"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1177\/10781552221126174","article-title":"Economic burden in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), with or without brain metastases, receiving first-line ALK inhibitors","volume":"29","author":"Wu","year":"2022","journal-title":"J Oncol Pharm Pract"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"3600","DOI":"10.1200\/JCO.2013.49.1845","article-title":"Cancer drugs in the United States: Justum Pretium--the just price","volume":"31","author":"Kantarjian","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1200\/JCO.2013.54.6002","article-title":"Cost effectiveness of crizotinib for anaplastic lymphoma kinase-positive, non-small-cell lung cancer: who is going to blink at the cost","volume":"32","author":"Kelly","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12962-020-00244-6","article-title":"Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong","volume":"18","author":"Loong","year":"2020","journal-title":"Cost Eff Resour Alloc"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s40273-021-01015-8","article-title":"The cost-effectiveness of Lorlatinib versus chemotherapy as a second-or third-line treatment in anaplastic lymphoma kinase (ALK)-positive non-small-cell lung Cancer in Sweden","volume":"39","author":"Nilsson","year":"2021","journal-title":"PharmacoEconomics"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1001\/jama.2015.16843","article-title":"Payer and policy maker steps to support value-based pricing for drugs","volume":"314","author":"Bach","year":"2015","journal-title":"JAMA"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1001\/jama.2014.13235","article-title":"Indication-specific pricing for cancer drugs","volume":"312","author":"Bach","year":"2014","journal-title":"JAMA"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1001\/jama.2018.15782","article-title":"Alternative state-level financing for hepatitis C treatment-the \u201cNetflix model\u201d","volume":"320","author":"Trusheim","year":"2018","journal-title":"JAMA"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.mayocp.2016.04.028","article-title":"The UK Cancer drugs fund experiment and the US Cancer drug cost problem: bearing the cost of Cancer drugs until it is unbearable","volume":"91","author":"Prasad","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1001\/jamaoncol.2015.0373","article-title":"Five years of Cancer drug approvals: innovation, efficacy, and costs","volume":"1","author":"Mailankody","year":"2015","journal-title":"JAMA Oncol"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1097\/JTO.0b013e31820cf053","article-title":"Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed","volume":"6","author":"Camidge","year":"2011","journal-title":"J Thorac Oncol"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/annonc\/mds242","article-title":"Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer","volume":"24","author":"Shaw","year":"2013","journal-title":"Ann Oncol"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.jval.2012.04.012","article-title":"Model transparency and validation: a report of the ISPOR-SMDM Modeling good research practices task force--7","volume":"15","author":"Eddy","year":"2012","journal-title":"Value Health"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2024.1213318\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T05:20:41Z","timestamp":1707974441000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2024.1213318\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,15]]},"references-count":68,"alternative-id":["10.3389\/fpubh.2024.1213318"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2024.1213318","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,15]]},"article-number":"1213318"}}